NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Tevard Biosciences

Tevard Biosciences

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://tevard.com/

Last Round

VC Round

May 20, 2026

Total Funding Raised

$5M

Company Overview

Tevard Biosciences is a biotechnology company that develops tRNA-based gene therapies to treat rare and severe genetic diseases by restoring functional proteins.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

tRNA therapygene therapysuppressor tRNAgenetic medicineprotein restorationbiotech platformrare disease therapyDuchenne muscular dystrophydilated cardiomyopathypreclinical researchbiotech startupdrug discoverygenetic engineeringnext-gen therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tevard Biosciences Comparables

Compare Tevard Biosciences with similar companies based on industry and business-model similarity.

Tevard Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Alltrna
94%
Shape Therapeutics
79%
Laronde
74%

Tevard Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMay 20, 2026
Convertible DebtDec 3, 2020

Key People

Founding team and executive leadership

Dan Lazzari

Chief Financial Officer

Executive Team

Tevard Biosciences Investors

Notable investors and investment history

Tevard Biosciences investors
InvestorRounds
Good Growth CapitalSeries A
CureDuchenne VenturesVC Round, Series A
Sherpa Healthcare PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 17, 2025

    Presented compelling full-length protein rescue data at the 2025 FEBS Special Meeting.

  • Nov 17, 2025

    Presented data at the 2025 FEBS Special Meeting.

Tevard Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Tevard Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Tevard Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range27
Year Founded2017
Last FundingMay 20, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.